首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   619篇
  国内免费   98篇
  完全免费   84篇
  综合类   801篇
  2020年   1篇
  2019年   1篇
  2018年   3篇
  2017年   32篇
  2016年   25篇
  2015年   29篇
  2014年   29篇
  2013年   32篇
  2012年   57篇
  2011年   78篇
  2010年   57篇
  2009年   65篇
  2008年   70篇
  2007年   75篇
  2006年   12篇
  2005年   13篇
  2004年   7篇
  2003年   12篇
  2002年   14篇
  2001年   2篇
  2000年   2篇
  1999年   6篇
  1998年   1篇
  1997年   21篇
  1996年   34篇
  1995年   19篇
  1994年   18篇
  1993年   13篇
  1992年   17篇
  1991年   11篇
  1990年   14篇
  1989年   11篇
  1988年   4篇
  1987年   7篇
  1986年   8篇
  1985年   1篇
排序方式: 共有801条查询结果,搜索用时 46 毫秒
1.
白花蛇舌草对H22肝癌细胞热休克蛋白70表达的影响   总被引:12,自引:1,他引:11  
【目的】观察H22肝癌细胞热休克蛋白70(HSP70)表达及清热解毒中药白花蛇舌草对其表达的影响。【方法】以培养的H22肝癌细胞腹腔接种于小鼠使小鼠致瘤,然后将荷瘤小鼠分为模型组、白花蛇舌草组(剂量为25 g/kg)、党参对照组(剂量为25 g/kg)及热休克处理组共4组。采用免疫组化标记法检测各组活体腹水H22肝癌细胞HSP70的表达情况。【结果】白花蛇舌草组及热休克处理组H22肝癌细胞HSP70的表达显著性高于模型组(P<0.05或P<0.01);党参对照组H22肝癌细胞的HSP70表达与模型组比较无显著性差异(P>0.05)。【结论】白花蛇舌草可能通过诱导H22肝癌细胞HSP70表达,增强其免疫原性而发挥抗肿瘤作用。  相似文献
2.
Clinical application of hepatic venous occlusion for hepatectomy   总被引:7,自引:1,他引:6       下载免费PDF全文
Background Most liver resections require clamping of the hepatic pedicle (Pringle maneuver) to avoid excessive blood loss. But Pringle maneuver can not control backflow bleeding of hepatic vein. Resection of liver tumors involving hepatic veins may cause massive hemorrhage or air embolism from the injuries of the hepatic veins. Although total hepatic vascular exclusion can prevent bleeding of the hepatic veins effectively, it also may result in systemic hemodynamic disturbance because of the inferior vena cava being clamped. Hepatic venous occlusion, a new technique, can control the inflow and outflow of the liver without clamping the vena cava. Methods A total of 71 cases of liver tumors underwent resection with occlusion of more than one of the main hepatic veins. All tumors involved the second porta hepatis and at least one main hepatic vein. Ligation or occlusion with serreflnes, tourniquets and auricular clamps were used in hepatic venous occlusion. Results Of the 71 patients, ligation of the hepatic veins was used in 28 cases, occlusion with a tourniquet in 26, and occlusion with a serrefine in 17. Right hepatic veins were occluded in 38 cases, both right and middle hepatic veins in 2, the common trunk of the left and middle hepatic veins in 24, branches of the left and middle hepatic veins in 2, and all three hepatic veins in 5. Thirty-five cases underwent hemihepatic vascular occlusion, 4 alternate hemihepatic vascular occlusion, 23 portal triad clamping plus selective hepatic vein occlusion, and 9 portal triad clamping plus total hepatic vein occlusion. The third porta hepatis was isolated in 26 cases. The amount of intraoperative blood loss averaged (540±2.83) (range 100 to 1000) ml in the group of total hemihepatic vascular occlusion and in the group of alternate hemihepatic vascular occlusion, (620±317) (range 200-6000) ml in the group of portal triad clamping plus selective or total hepatic vein occlusion. All tumors were completely removed. Conclusions Hepatic venous occlusion  相似文献
3.
六味地黄丸对小鼠移植性肝癌自杀基因治疗的增效作用   总被引:7,自引:4,他引:3  
【目的】观察六味地黄丸对小鼠皮下移植性肝细胞癌自杀基因治疗的增效作用,探讨建立中西医结合肿瘤自杀基因联合治疗方案的可行性。【方法】培养病毒包装细胞PT67/tk,病毒上清感染肝细胞癌细胞株H22后用G418筛选2周,获得抗性细胞克隆,命名为H22/tk并进行体外丙氧鸟苷(GCV)杀伤试验;证明杀伤活性后,将H22/tk与野生型H22按1∶4的比例混合后接种于昆明种小鼠皮下组织内造模,分为模型对照组、自杀基因治疗组、六味地黄丸治疗组和联合治疗组(N=20),并设正常对照组(N=10);六味地黄丸治疗从接种第2天起共15 d,GCV治疗从接种第6天起共11 d,观察疗效。【结果】体外实验中GCV对H22/tk肿瘤细胞具有明显的杀伤效应,表明体外病毒感染肝癌细胞成功,病毒携带的外源性自杀基因已表达且具有生物学活性。体内实验中于接种肿瘤细胞后第6天各组能触摸到肿瘤,成瘤率100%。自杀基因联合六味地黄丸治疗对小鼠移植性肝细胞癌生长速度具有明显抑制作用,以瘤块质量计算,其抑瘤率为63.0%(P<0.05);而单纯六味地黄丸治疗和单纯自杀基因治疗抑瘤率分别为46.3%和37.4%,但两者与模型组比较差异均无显著性意义。病理检查:各治疗组肉眼可见肿瘤体积均较模型对照组肿瘤体积小,以联合治疗组更明显。镜下可见各治疗组肿瘤细胞密度相对较低,肿瘤周围有较多纤维结缔组织增生及炎症细胞浸润,联合治疗组更明显,各组间差别以炎症细胞浸润最突出。【结论】六味地黄丸对小鼠移植性肝癌自杀基因治疗具有一定的增效作用,其疗效优于单纯自杀基因疗法或单纯六味地黄丸治疗。  相似文献
4.
MACC1基因在肝细胞癌中的表达及临床意义   总被引:5,自引:0,他引:5  
目的 探讨MACC1基因在肝细胞癌(hepatocellular carcinoma,HCC)中的表达及其临床意义.方法 应用逆转录聚合酶链反应(RT-PCR)方法 检测42例肝癌组织、对应癌旁肝组织以及17例正常肝组织中MACC1 mRNA的表达情况,并分析MACC1基因的表达与相关临床参数的关系.结果 MACC1基因在肝癌组织的表达水平显著高于癌旁肝组织(P<0.01),在癌旁肝组织的表达水平显著高于正常肝组织(P<0.05),且MACC1基因的表达水平与肝癌的TNM分期、肝内或淋巴结转移、门静脉癌栓等均明显相关(均P<0.05),而与肿瘤个数、血清甲胎蛋白(AFP)水平、有无肝硬化等无明显关系(均P>0.05).结论 MACC1基因可能在肝细胞癌的侵袭转移中发挥着重要作用,有可能成为肝癌治疗的新靶点之一.  相似文献
5.
Background The earthworm fibrinolytic enzyme (EFE) is a complex protein enzyme that is widely distributed in the earthworm’s digestive cavity. Possessing strong protein hydrolysis activity, EFE not only has a direct effect on fibrin, but also can activate plasminogen. Its therapeutic and preventative effects on thrombosis-related disease have been confirmed clinically. Recently, there has been increased interest in the anti-tumor activity of EFE. In this study, the anti-tumor activity of EFE, isolated from Eisenia foetida, on human hepatoma cells was evaluated in vitro and in vivo. The potential mechanisms involved were also studied. Methods In vitro experiments were performed in four human hepatoma cell lines: HLE, Huh7, PLC/PRF/5 and HepG2. After treatment with EFE in various concentrations, the inhibition of the rate of cell proliferation was measured. For the in vivo studies, tumor-bearing models xenografted with Huh7 cells were developed in nude mice, and then the mice were fed with EFE once a day for 4 weeks, and the control group received only saline. An inhibitory effect on tumor growth was observed. Also, apoptosis was observed with flow cytometric assay and fluorescent dye staining with acridine orange and ethidium bromide (AO/EB). The expression of matrix metalloproteinase 2 (MMP-2) were detected by Western blotting assay.Results After treatment with various concentrations of EFE, the proliferation of all hepatoma cell lines was suppressed to varying degrees in vitro. The IC(50) for HLE, Huh7, PLC/PCF/5 and HepG2 were 2.11, 5.87, 25.29 and 17.30 uku/ml, respectively. After administration of EFE orally for 4 weeks, the growth of tumor xenograft of Huh7 cells in nude mice was significantly inhibited in vivo. The tumor inhibitory rates in the EFE 500 uku/(kg·d) and 1000 uku/(kg·d) groups were 46.08% (compared with control group, P=0.026) and 57.52% (compared with control group, P=0.002) respectively. Meanwhile, the average weight of body, spleen or thymus did not show any remarkable differences among the various groups. The population in sub-G(1) stage was more in the EFE treated groups than in the control group according to flow cytometric assay. After treatment with EFE 0, 5, 10 uku/ml for 72 hours, the apoptotic rates were 3.5%, 10.9% and 12.3% in HLE cells, and 5.0%, 24.7% and 34.5% in Huh7 cells respectively. Under fluorescent staining with AO/EB, the apoptotic morphological changes could be detected more significantly in the EFE treated groups than in the untreated groups. After treatment with EFE in doses of 0, 5, 10 uku/ml for 72 hours, the apoptotic rates were 3.02%, 8.76%, 10.54% in HLE cells, and 3.95%, 18.27%, 30.89% in Huh7 cells respectively. The apoptosis-inducing effects of EFE occurred in a dose dependent manner. Western blotting assay showed that, after treatment with EFE, the secretions of MMP-2 were significantly inhibited in HLE and Huh7 cells.Conclusions EFE showed significant anti-tumor activity in hepatoma cells both in vitro and in vivo, which may be because EFE could induce apoptosis of hepatoma cells and inhibit the expression of MMP-2. This suggests that EFE has a potential role in the treatment of hepatoma.  相似文献
6.
肝脏血管平滑肌脂肪瘤的影像学及病理学分析   总被引:5,自引:0,他引:5  
目的:分析肝脏血管平滑肌脂肪瘤的CT及MR I的影像学特点与病理基础,减少对该肿瘤的误诊。方法:回顾性分析10例肝血管平滑肌脂肪瘤患者的CT及MR I影像学表现,并与病理组织学对照分析。结果:在10例肝脏血管平滑肌脂肪瘤中,脂瘤型3例,血管瘤型1例,肌瘤型1例,混合型5例。脂瘤型以脂肪成分为主,CT、MR I显示脂肪密度或信号。血管瘤型以血管成分为主,CT、MR I增强可见动脉期明显强化,门静脉期密度或信号仍高于同期肝实质。肌瘤型主要是由平滑肌成分为主,脂肪成分很少。混合型3种成分含量相似,平扫CT为较均匀低密度,MR I T 1W呈低信号,T 2W呈稍高信号;增强扫描CT、MR I均呈动脉期明显强化,门静脉期仍有强化。结论:不同病理组织学类型的肝脏血管平滑肌脂肪瘤,CT和MR I表现有所不同,这取决于肿瘤所含的主要组织学成分。  相似文献
7.
人肝癌组织中nm23-H1基因突变的检测及意义   总被引:5,自引:3,他引:2  
目的观察肿瘤转移抑制基因nm23-H1在人原发性肝细胞癌中的突变情况,探讨nm23-H1基因突变与肝癌发生、发展及转移的关系。方法采用聚合酶链反应-单链构象多态性技术(PCR-SSCP),对16例肝癌组织、12例癌旁组织和4例正常肝组织的nm23-H1基因的第1、2、4外显子突变情况突变进行检测。结果肝癌组织中有1例nm23-H1基因第1外显子纯合缺失;肝癌组织中1例第1外显子、1例第2外显子,癌旁组织中2例第2外显子有单链DNA泳动变位。结论nm23-H1基因突变在肝癌组织中发生率低。  相似文献
8.
Background Radiofrequency ablation (RFA) followed by transarterial chemoembolization (TACE) for unresectable primary liver cancer (PLC) has not been widely discussed. In this study, the outcome of the combination of RFA with TACE was retrospectively evaluated. Methods From May 2003 to March 2008, 127 consecutive PLC patients with a median age of 56.4+8.8 years underwent RFA plus TACE. All patients were deemed to have unresectable PLC based on their tumor characteristics. The maximal diameter of the tumor was between 1.5 cm and 10.0 cm. Twenty-six cases with small (〈3.0 cm), 33 with medium (3.1-5.0 cm), and 68 with large (〉5.0 cm) tumors were included in this study. RFA was performed using a RITA Medical Systems expandable electrode device, which was followed by first-time TACE administration one to two months later. Results Technical success of RFA was achieved in all 127 patients with no severe treatment-related complications. RFA was performed percutaneously in 16 (13.5%) cases, by laparoscopic approach in 19 (15.7%), and through laparotomy in the remaining 92 (72.4%). RFA response was classified as complete ablation in 48 cases, nearly complete ablation in 28, and partial ablation in 51. The total 1-, 2-, and 3-year survival rates after RFA were 83.1%, 55.7%, and 43.7%, respectively. The survival rates at 3 years were 78.6%, 28.1%, and 0 for complete ablation, nearly complete ablation, or partial ablation groups, respectively. Three-year disease-free survival rates for the complete ablation and nearly complete ablation groups were 50.3% and 21.3%, respectively. RFA response and liver function were significant variables influencing survival time as analyzed using the Cox regression model. Conclusion RFA could be the first-line exterminate treatment for unresectable PLC, and TACE following RFA may assist in eradicatinq the peripheral viable tissue and micro-metastasis.  相似文献
9.
紫草素对肝癌细胞增殖的影响   总被引:4,自引:0,他引:4  
目的研究紫草素对肝癌细胞株HepG2增殖和表达增殖诱导配体(A proliferation-inducing ligand,APRIL)水平的影响,并与化疗药顺铂进行对比。方法MTT法检测紫草素对HepG2细胞增殖的抑制作用,采用免疫组化法和实时荧光定量PCR法证实肝癌细胞株HepG2上APRIL的表达,实时荧光定量PCR法检测加入不同终浓度的紫草素和顺铂后24h、48h和72h HepG2细胞表达APRIL mRNA的水平。结果紫草素对HepG2细胞有明显的增殖抑制作用,呈时间和剂量依赖性,HepG2细胞上有APRIL的表达,加入不同浓度的紫草素和顺铂后,HepG2细胞A-PRIL mRNA的水平均逐渐升高,至72h表达最高并与空白对照相比均有显著差异(P〈0.05)。结论紫草素可抑制肝癌细胞的增殖,但与顺铂一样,残存癌细胞有因APRIL表达升高而增殖能力增强的潜在趋势。  相似文献
10.
肝癌肝移植术后复发及肝外转移瘤的125I粒子植入治疗   总被引:4,自引:1,他引:3  
Zhang FJ  Li CX  Wu PH  Li K  Huang JH  Fan WJ  Zhang L  Gu YK  Lu MJ  Wu YX  Wang JJ 《中华医学杂志》2007,87(14):956-959
目的评价CT导向下^125I粒子植入术治疗肝癌肝移植术后复发及肝外转移瘤的临床价值。方法肝癌肝移植术后复发及肝外转移瘤患者11例行^125I粒子植入术共33人次,年龄35—68岁,中位年龄56岁。所有患者病灶总数为45个,平均每人4.09个病灶,病灶平均直径为2.5cm。术前采用治疗计划系统(TPS)计算布源,术中将活度为30MBq的^125I粒子在CT导向下植入肿瘤病灶内。粒子按照0.5—1.0cm平面插植。肿瘤周边匹配剂量(MPD)100—150Gy,每个患者植入粒子数10—100颗不等。结果45个病灶,完全缓解(CR)17个;部分缓解(PR)20个;无变化(NC)7个;进展(PD)1个。总有效率为82.2%。术中1例出现气胸,肺压缩在30%以内,经保守治疗好转,手术中少量出血者3例;术后1周痰中带血,体温升高者5例。2个月随访过程中发生粒子移位2例;白细胞下降2例,程度较轻。未见大出血、胆汁瘘、胰瘘等严重并发症。结论CT导向下^125I粒子植入术治疗肝癌肝移植术后复发及转移瘤疗效确切,创伤小,并发症少。  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号